EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular toxicity from therapies for light chain amyloidosis

Paolo Morfino, Alberto Aimo, Vincenzo Castiglione, Michela Chianca, Giuseppe Vergaro, Carlo Maria Cipolla, Antonella Fedele, Michele Emdin, Iacopo Fabiani, Daniela Cardinale

Frontiers in Cardiovascular Medicine · 05.07.2023 · 10

DOI: 10.3389/fcvm.2023.1212983 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 05.07.2023. Verfasst von Paolo Morfino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyloid light-chain (AL) amyloidosis is a hematological disorder characterized by abnormal proliferation of a plasma cell clone producing monoclonal free light chains that misfold and aggregate into insoluble fibrils in various tissues. Cardiac involvement is a common feature leading to restrictive cardiomyopathy and poor prognosis. Current first-line treatments aim at achieving hematological response by targeting the plasma cell clones, and these have been adapted from multiple myeloma therapy. Patients with AL amyloidosis often exhibit multiorgan involvement, making them susceptible to cancer therapy-related cardiovascular toxicity. Managing AL amyloidosis is a complex issue that requires enhanced knowledge of the cardio-oncological implications of hematological treatments. Future research should focus on implementing and validating primary and secondary prevention strategies and understanding the biochemical basis of oncological therapy-related damage to mitigate cardiovascular toxicity.

Schlagwörter

Stichwörter der Autor:innen

AL amyloidosiscardiac amyloidosiscardiovascular toxicitychemotherapytreatment

Autor:innen und Institutionen

  • Interdisciplinary Center for Health Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
  • Cardioncology Unit, Cardioncology and Second Opinion Division, European Institute of Oncology, I.R.C.C.S., Milan, Italy.

Zitieren

APA

Morfino, P., Aimo, A., Castiglione, V., Chianca, M., Vergaro, G., Cipolla, C. M., Fedele, A., Emdin, M., Fabiani, I., & Cardinale, D. (2023). Cardiovascular toxicity from therapies for light chain amyloidosis. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1212983

Vancouver

Morfino P, Aimo A, Castiglione V, Chianca M, Vergaro G, Cipolla CM, et al. Cardiovascular toxicity from therapies for light chain amyloidosis. Frontiers in Cardiovascular Medicine. 2023;10. doi:10.3389/fcvm.2023.1212983

BibTeX
@article{Morfino2023,
  author = {Morfino, Paolo and Aimo, Alberto and Castiglione, Vincenzo and Chianca, Michela and Vergaro, Giuseppe and Cipolla, Carlo Maria and Fedele, Antonella and Emdin, Michele and Fabiani, Iacopo and Cardinale, Daniela},
  title = {Cardiovascular toxicity from therapies for light chain amyloidosis},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  volume = {10},
  doi = {10.3389/fcvm.2023.1212983}
}
Kostenlos starten →